Turn Therapeutics提交8-K自願披露新聞稿 細節未公開僅供參考

false
 0002023016
 
 
 
 
 
 
 
 0002023016
 
 
 2026-05-18
 2026-05-18
 
 
 
 iso4217:USD
 
 
 xbrli:shares
 
 
 
 
 iso4217:USD
 
 
 xbrli:shares
 
 
 
 
 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported):
May 18, 2026

 

TURN THERAPEUTICS
INC.

(Exact name of registrant as specified in its charter)

 

 
 Delaware
  
 001-42875
  
 32-0456090

 
 (State or other jurisdiction of

incorporation)
  
 (Commission File Number)
  
 (IRS Employer

Identification Number)

 
 

 
 250 N. Westlake Blvd., Westlake Village, California
  
 91362

 
 (Address of principal executive offices)
  
 (Zip Code)

 
 

Registrant’s telephone number, including
area code: (818) 564-4011

 

N/A

(Former name or former address, if changed since
last report)

 

Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

 
 ¨
 Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 
 

 
 ¨
 Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 
 

 
 ¨
 Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 
 

 
 ¨
 Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 
 

Securities registered pursuant to Section 12(b) of the Act:

 

 
 Title of Each Class 
  
 Trading Symbol 
  
 Name of Each Exchange on Which Registered 

 
 Common Stock, par value $0.0001 per share
  
 TTRX
  
 The Nasdaq Stock Market LLC

 
 

Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the
Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☒

 

If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

  

 

 

 
 Item 7.01
 Regulation FD Disclosure.

 
 

On May 18, 2026, Turn Therapeutics
Inc. issued a press release (the “Press Release”). A copy of the Press Release is furnished as Exhibit 99.1 to this Current
Report on Form 8-K.

 

The information in Item 7.01
of this Current Report on Form 8-K and the Press Release furnished as Exhibit 99.1 hereto shall not be deemed “filed” for
purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the
liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended,
or the Exchange Act, except as expressly set forth by specific reference in such a filing.

 

 
 Item 9.01
 Financial Statements and Exhibits.

 
 

(d) Exhibits

 

 
 Exhibit No. 
  
 Description 

 
 99.1
  
 Press Release, dated May 18, 2026

 
 104
  
 Cover Page Interactive Data File (embedded within the Inline XBRL document)

 
 

 1

  

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 
  
 TURN THERAPEUTICS INC.

 
 Date: May 18, 2026
  

 
  
  

 
  
 By:
 /s/ Bradley Burnam

 
  
 Name:
 Bradley Burnam

 
  
 Title:
 Chief Executive Officer

 
 

 2